Company intelligence / Profile preview

Acurx Pharmaceuticals, Inc.

Staten Island, New York, United Statesacurxpharma.com ↗

Ownership: Public · ACXP
Development stage: Other

Overview

Acurx has completed Phase 2b clinical trials for its lead candidate ibezapolstat for C. difficile infection. The Phase 2a trial demonstrated 100% clinical cure at end of treatment and 100% sustained clinical cure in patients with CDI. The company has received FDA agreement on key elements to move forward with its international Phase 3 clinical trial program and is preparing for Phase 3 trials.[6][8]

Therapeutic areas: Infectious Diseases
Modalities: Small moleculesAntibiotics
Industry: Biotech

Drug pipeline

3 assets

ibezapolstat

2 more assets in the full pipeline.

Financials

Market cap: $5.3M
Total revenue: $0
Enterprise value: $-5.4M

Beyond the preview

Go deeper on Acurx Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acurx Pharmaceuticals, Inc..